GRAIL's Galleri Test Volume Surges 50% as FDA Review Nears
Event summary
- GRAIL's Galleri test volume grew 50% year-over-year to over 56,000 tests in Q1 2026.
- Total revenue increased 28% year-over-year to $40.8 million, with Galleri revenue up 37% to $39.8 million.
- Net loss improved by $13 million to $93.2 million, with adjusted gross profit rising 38% to $19.7 million.
- GRAIL submitted a Premarket Approval (PMA) application for Galleri to the FDA in January 2026.
- Planned integration of Galleri into Epic's EHR platform expected by the end of 2026.
The big picture
GRAIL's strong Q1 2026 results highlight the growing demand for its Galleri multi-cancer early detection test, particularly as it navigates the critical FDA review process. The planned integration with Epic's EHR platform could significantly expand access, positioning Galleri as a key player in the multi-cancer early detection market. The upcoming presentation of clinical data at ASCO will be pivotal in shaping investor and market confidence in the test's efficacy and potential.
What we're watching
- Regulatory Approval
- The outcome of the FDA's review of Galleri's PMA application, which could determine the test's broader market availability.
- Market Expansion
- The success of integrating Galleri into Epic's EHR platform and its impact on test adoption and revenue growth.
- Clinical Data
- The presentation of detailed results from the NHS-Galleri trial and PATHFINDER 2 study at the 2026 ASCO Annual Meeting and their potential influence on market perception.
Related topics